Baidu
map

PLoS Med:他汀类药物或不能预防静脉血栓的形成

2012-09-20 T.Shen 生物谷

近日,刊登在国际杂志PLOS Medicine上的一篇研究报告中,来自牛津大学等机构的一个国际小组研究发现,在成年人中,降胆固醇的他汀类药物或许并不能预防血凝块(blood clots,一种静脉血栓栓塞)。 2009年时,一项名为JUPITER随机试验结果报道了,他汀类药物罗舒伐他汀在健康人群中可以使得静脉血栓事件风险减半。然而本项研究是基于一小部分血栓栓塞病人进行的研究。为了获得更多的关于他汀

近日,刊登在国际杂志PLOS Medicine上的一篇研究报告中,来自牛津大学等机构的一个国际小组研究发现,在成年人中,降胆固醇的他汀类药物或许并不能预防血凝块(blood clots,一种静脉血栓栓塞)。

2009年时,一项名为JUPITER随机试验结果报道了,他汀类药物罗舒伐他汀在健康人群中可以使得静脉血栓事件风险减半。然而本项研究是基于一小部分血栓栓塞病人进行的研究。为了获得更多的关于他汀类药物的可能临床效应,研究者对29项他汀类药物随机试验的数据以及超过1000项血栓栓塞事件进行结合分析。

在结合分析过程中,研究者发现,未服用他汀类药物的人群静脉血栓形成发生率为1%,然而服用他汀类药物的人群血栓发生率只是0.9%。研究者同时发现,随着他汀类药物剂量的改变,丝毫不会影响静脉血栓形成的发生率。

研究者总结道,这项研究提供了他汀类药物对于血栓形成影响的一些数据和信息,当然我们并不能确定以前研究中所指出的大量随机性血栓形成风险的降低结果。然而在世界范围内并不排除有许多类型的病人确实在服用他汀类药物后静脉血栓形成发生了明显的降低。

拓展阅读:
               

  • 研究表明他汀类药物可能有助抗癌
  • JAMA:他汀类药物可降低胰腺炎发病风险
  • Lancet:服用他汀类药物降低心血管疾病的患病风险优于患糖尿病的风险
  • NEJM述评:他汀类药物 获益仍然远大于风险
  • Arch Intern Med:他汀类药物副作用新添“成员”——疲劳
  • Lancet:Meta分析表明他汀类药物可有效用于一级预防
  • 2012 AAN年会:他汀类或降低卒中早期死亡率
  • The Cochrane Library:CABG前他汀类治疗可降低术后房颤风险
  • 荟萃分析显示CABG前使用他汀类药物可降低术后房颤风险
  • Stroke:停用他汀类药物影响颅内出血转归
  • 他汀类药物安全性调查引起的大讨论
  • Arch Neuro:他汀类药物可明显降低帕金森病的发病风险
  • FDA修改了他汀类药物安全信息
  • BJC:联合使用他汀类药物和紫杉醇可有效引发癌细胞凋亡
  • J Hepatol:警惕他汀类药物相关肝毒性
  • Cancer:他汀类药与致命性前列腺癌死亡率下降相关
  • IJC:他汀类强化治疗益处仅限于非致死性事件
  • BMJ:他汀类药物未能降低感染风险
  • 版权声明:
    本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
    在此留言
    评论区 (7)
    #插入话题
    1. [GetPortalCommentsPageByObjectIdResponse(id=377874, encodeId=bd7f3e7874ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jan 06 23:27:58 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377490, encodeId=78833e749028, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Dec 27 15:51:15 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377485, encodeId=3da23e7485c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Dec 27 12:52:09 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044324, encodeId=4570204432459, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Jul 17 08:30:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955168, encodeId=cb7719551684f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Dec 27 08:30:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697146, encodeId=c28a169e14659, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jun 01 16:30:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605831, encodeId=4293160583145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 22 01:30:00 CST 2012, time=2012-09-22, status=1, ipAttribution=)]
      2020-01-06 天地飞扬

      学习

      0

    2. [GetPortalCommentsPageByObjectIdResponse(id=377874, encodeId=bd7f3e7874ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jan 06 23:27:58 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377490, encodeId=78833e749028, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Dec 27 15:51:15 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377485, encodeId=3da23e7485c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Dec 27 12:52:09 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044324, encodeId=4570204432459, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Jul 17 08:30:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955168, encodeId=cb7719551684f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Dec 27 08:30:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697146, encodeId=c28a169e14659, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jun 01 16:30:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605831, encodeId=4293160583145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 22 01:30:00 CST 2012, time=2012-09-22, status=1, ipAttribution=)]
      2019-12-27 130****4638

      学习了,谢谢分享

      0

    3. [GetPortalCommentsPageByObjectIdResponse(id=377874, encodeId=bd7f3e7874ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jan 06 23:27:58 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377490, encodeId=78833e749028, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Dec 27 15:51:15 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377485, encodeId=3da23e7485c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Dec 27 12:52:09 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044324, encodeId=4570204432459, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Jul 17 08:30:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955168, encodeId=cb7719551684f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Dec 27 08:30:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697146, encodeId=c28a169e14659, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jun 01 16:30:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605831, encodeId=4293160583145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 22 01:30:00 CST 2012, time=2012-09-22, status=1, ipAttribution=)]
      2019-12-27 天地飞扬

      学习

      0

    4. [GetPortalCommentsPageByObjectIdResponse(id=377874, encodeId=bd7f3e7874ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jan 06 23:27:58 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377490, encodeId=78833e749028, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Dec 27 15:51:15 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377485, encodeId=3da23e7485c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Dec 27 12:52:09 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044324, encodeId=4570204432459, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Jul 17 08:30:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955168, encodeId=cb7719551684f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Dec 27 08:30:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697146, encodeId=c28a169e14659, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jun 01 16:30:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605831, encodeId=4293160583145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 22 01:30:00 CST 2012, time=2012-09-22, status=1, ipAttribution=)]
    5. [GetPortalCommentsPageByObjectIdResponse(id=377874, encodeId=bd7f3e7874ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jan 06 23:27:58 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377490, encodeId=78833e749028, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Dec 27 15:51:15 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377485, encodeId=3da23e7485c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Dec 27 12:52:09 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044324, encodeId=4570204432459, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Jul 17 08:30:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955168, encodeId=cb7719551684f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Dec 27 08:30:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697146, encodeId=c28a169e14659, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jun 01 16:30:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605831, encodeId=4293160583145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 22 01:30:00 CST 2012, time=2012-09-22, status=1, ipAttribution=)]
    6. [GetPortalCommentsPageByObjectIdResponse(id=377874, encodeId=bd7f3e7874ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jan 06 23:27:58 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377490, encodeId=78833e749028, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Dec 27 15:51:15 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377485, encodeId=3da23e7485c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Dec 27 12:52:09 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044324, encodeId=4570204432459, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Jul 17 08:30:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955168, encodeId=cb7719551684f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Dec 27 08:30:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697146, encodeId=c28a169e14659, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jun 01 16:30:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605831, encodeId=4293160583145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 22 01:30:00 CST 2012, time=2012-09-22, status=1, ipAttribution=)]
      2013-06-01 fusion
    7. [GetPortalCommentsPageByObjectIdResponse(id=377874, encodeId=bd7f3e7874ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jan 06 23:27:58 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377490, encodeId=78833e749028, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Dec 27 15:51:15 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377485, encodeId=3da23e7485c1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Dec 27 12:52:09 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044324, encodeId=4570204432459, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Jul 17 08:30:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955168, encodeId=cb7719551684f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Dec 27 08:30:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697146, encodeId=c28a169e14659, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jun 01 16:30:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605831, encodeId=4293160583145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 22 01:30:00 CST 2012, time=2012-09-22, status=1, ipAttribution=)]

    相关资讯

    NEJM述评:他汀类药物 获益仍然远大于风险

    近期还有一些研究以及meta分析指出他汀类药物的使用可能导致新发糖尿病的增加,针对这一问题,来自哈佛大学Joslin 糖尿病研究中心的Allison Goldfine教授在近期的《新英格兰医学杂志》上发表了述评,题为“他汀类药物:真的到了重新评估风险和利益的时候吗?” 毋庸置疑的是大量研究证实他汀类药物可以使急性冠脉综合征或冠心病患者明显获益,这种获益表现为有效地降低全因死亡、心血管疾病死亡、致

    Arch Intern Med:他汀类药物副作用新添“成员”——疲劳

    近来许多研究报告表明,他汀类药物可能会引起一些人疲劳,近日完成的一项随机试验为这一观点提供了确凿证据。 相关研究论文发表在Archives of Internal Medicine杂志上,研究募集了0岁以上的1016名健康男性和女性,这些参试者体内血液中低密度脂蛋白水平或“坏”胆固醇水平从每分升115到190毫克不等。三分之一的参试者每天给予20毫克的辛伐他汀,三分之一参试者给予40毫克的普

    探讨透析患者的调脂治疗

    作者:北京大学第一医院肾内科 北京大学肾脏病研究所 许戎 董捷        透析患者的血脂异常发生率显著高于一般人群。患者主要表现为甘油三酯(TG)水平升高、高密度脂蛋白胆固醇(HDL-C)水平下降,总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)水平在血液透析(简称血透)患者中可正常甚至下降,在腹膜透析(简称腹透)患者中却升高。然而,在透析患者中,关

    研究表明他汀类药物可能有助抗癌

    瑞士苏黎世联邦理工学院9月3日宣布,该校人员参与的一项研究表明,通常用于抗高血脂的他汀类药物可能有助于抗癌。 据瑞士媒体3日报道,来自苏黎世联邦理工学院和美国加利福尼亚大学伯克利分校的研究人员研发出一种细胞培养系,并使用这一细胞系对1000余种物质进行测试。测试中他们发现30多种物质具备抑制淋巴管发育的作用,并对其中两种物质进行详细分析,这两种物质中的一种属于他汀类药物。 研究人员说,淋巴管发

    Lancet:服用他汀类药物降低心血管疾病的患病风险优于患糖尿病的风险

    近日,刊登在国际著名医学杂志The Lancet上的一篇研究报告指出,对服用降胆固醇药物的病人进行实验发现,他汀类药物在降低心脏血管疾病风险上的效用优于患者增加糖尿病患病的风险。 研究者分析了来自朱庇特研究中心收集的数据,第一项对照研究组的数据揭示了服用他汀类药物可以导致糖尿病风险的增加,这项结果随后被很多类似研究证实了。 随后研究者继续分析了朱庇特研究中心收集的数据,旨在发现是否增加的糖尿病

    [DDW2012]肝硬化患者应用他汀药物安全有益

           一项来自2012年美国消化疾病周(Digestive Disease Week,DDW)的报告显示,他汀治疗对于肝硬化患者不仅是安全的,还可能延缓肝脏疾病进展至肝功能失代偿,延长患者寿命。          因为安全性方面的顾虑,一些临床医生对于晚期肝

    Baidu
    map
    Baidu
    map
    Baidu
    map